Simone Seiter
Director/Miembro de la Junta en GENSIGHT BIOLOGICS S.A. .
Cargos activos de Simone Seiter
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Director/Miembro de la Junta | 19/04/2017 | - |
| Independent Dir/Board Member | 19/04/2017 | - | |
Priothera SAS
 Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The private company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Director Técnico/Científico/I+D | - | - |
| Fundador | - | - |
Historial de carrera de Simone Seiter
Antiguos cargos conocidos de Simone Seiter.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| IQVIA | Corporate Officer/Principal | 01/01/2006 | 01/01/2019 |
| Simon-Kucher & Partners, Inc. | Corporate Officer/Principal | 01/01/2020 | - |
Formación de Simone Seiter.
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
| Neu-Ulm University of Applied Sciences | Masters Business Admin |
Estadísticas
Internacional
| Alemania | 4 |
| Francia | 3 |
| Canadá | 2 |
Operativa
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Sectorial
| Consumer Services | 3 |
| Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Empresas privadas | 3 |
|---|---|
| IQVIA | |
| Simon-Kucher & Partners, Inc. | |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The private company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Health Technology |
- Bolsa de valores
- Insiders
- Simone Seiter
- Experiencia
